Download the full announcement
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, refers to its announcement dated 3 October 2017 (the "Previous Announcement") and confirms that with effect from 22 December 2017 it will cancel 78,113 of the 205,561 Compensation Shares (as defined in the Previous Announcement (the "Cancellation"). EKF also confirms that the remaining 127,448 ordinary shares have been sold by one of the Majority Shareholders (as defined in the Previous Announcement) and the net proceeds of sale have been received by the Company.
Following the Cancellation, the Company's total issued share capital will consist of 457,554,636 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company will not hold any Ordinary Shares in treasury.
Therefore, the total number of voting rights in the Company will be 457,554,636.
The above figure of 457,554,636 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
|EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Julian Baines, CEO
Richard Evans, FD & COO
Tel: 029 2071 0570
|N+1 Singer (Nomad & Broker)
Alex Price / Shaun Dobson / Ali Laughton-Scott
|Tel: 020 7496 3000
Walbrook PR Limited
|Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303